FindTrial
Sign In

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03206931
Enrollment
Unknown
Registered
2017-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors Harboring NTRK Fusion

Keywords

Metastatic cancer, Advanced cancer, Neurotrophic tyrosine receptor kinase (NTRK), NTRK1, NTRK2, NTRK3, Fusion Positive, Children, Loxo-195

Brief summary

Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Interventions

DRUGSelitrectinib (BAY2731954)

Selitrectinib is administered as capsules or liquid formulation.

Sponsors

Bayer
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
1 Months to No maximum

Inclusion criteria

* Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion * Previous treatment with a kinase inhibitor with known activity on TRK inhibition * Unable to participate in an ongoing selitrectinib clinical trial * Medically suitable for treatment with selitrectinib

Exclusion criteria

* Currently enrolled in an ongoing clinical study with a TRK inhibitor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026